170 related articles for article (PubMed ID: 25392102)
1. IMPDH2 mediate radioresistance and chemoresistance in osteosarcoma cells.
Li HX; Meng QP; Liu W; Li YG; Zhang HM; Bao FC; Song LL; Li HJ
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3038-44. PubMed ID: 25392102
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells.
Fellenberg J; Kunz P; Sähr H; Depeweg D
PLoS One; 2010 Aug; 5(8):e12179. PubMed ID: 20808934
[TBL] [Abstract][Full Text] [Related]
3. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
[TBL] [Abstract][Full Text] [Related]
4. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Huang Z; Huang Y; He H; Ni J
Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
[TBL] [Abstract][Full Text] [Related]
5. GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy.
Kim M; Jung JY; Choi S; Lee H; Morales LD; Koh JT; Kim SH; Choi YD; Choi C; Slaga TJ; Kim WJ; Kim DJ
Autophagy; 2017 Jan; 13(1):149-168. PubMed ID: 27754745
[TBL] [Abstract][Full Text] [Related]
6. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
[TBL] [Abstract][Full Text] [Related]
7. IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma.
Chaiyawat P; Phanphaisarn A; Sirikaew N; Klangjorhor J; Thepbundit V; Teeyakasem P; Phinyo P; Pruksakorn D; Settakorn J
Sci Rep; 2021 May; 11(1):10887. PubMed ID: 34035425
[TBL] [Abstract][Full Text] [Related]
8. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.
Li C; Cai J; Ge F; Wang G
Int J Mol Med; 2018 Oct; 42(4):1799-1808. PubMed ID: 30015899
[TBL] [Abstract][Full Text] [Related]
9. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
[TBL] [Abstract][Full Text] [Related]
10. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived osteosarcoma cells are resistant to methotrexate.
Dos Santos Cavalcanti A; Meohas W; Ribeiro GO; de Sá Lopes AC; Gholamin S; Razavi M; Hanae Kasai Brunswick T; Avan A; Matheus Guimarães JA; Leite Duarte ME; Kahn SA
PLoS One; 2017; 12(9):e0184891. PubMed ID: 28934267
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
13. PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.
Cheng C; Ding Q; Zhang Z; Wang S; Zhong B; Huang X; Shao Z
J Cell Mol Med; 2020 May; 24(9):5274-5289. PubMed ID: 32207235
[TBL] [Abstract][Full Text] [Related]
14. LY2109761 inhibits metastasis and enhances chemosensitivity in osteosarcoma MG-63 cells.
Ren XF; Mu LP; Jiang YS; Wang L; Ma JF
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1182-90. PubMed ID: 25912577
[TBL] [Abstract][Full Text] [Related]
15. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
[TBL] [Abstract][Full Text] [Related]
17. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.
He C; Sun J; Liu C; Jiang Y; Hao Y
Clin Epigenetics; 2019 Jan; 11(1):8. PubMed ID: 30651137
[TBL] [Abstract][Full Text] [Related]
18. HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.
Wang H; Sun W; Sun M; Fu Z; Zhou C; Wang C; Zuo D; Zhou Z; Wang G; Zhang T; Xu J; Chen J; Wang Z; Yin F; Duan Z; Hornicek FJ; Cai Z; Hua Y
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1839-1849. PubMed ID: 29524631
[TBL] [Abstract][Full Text] [Related]
19. Role of aldolase A in osteosarcoma progression and metastasis: in vitro and in vivo evidence.
Long F; Cai X; Luo W; Chen L; Li K
Oncol Rep; 2014 Nov; 32(5):2031-7. PubMed ID: 25215901
[TBL] [Abstract][Full Text] [Related]
20. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.
Orosco A; Fromigué O; Bazille C; Entz-Werle N; Levillain P; Marie PJ; Modrowski D
Cancer Res; 2007 Apr; 67(8):3708-15. PubMed ID: 17440083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
